H.C. Wainwright Starts Kadmon Holdings (KDMN) at Buy

August 22, 2016 8:02 AM EDT
Get Alerts KDMN Hot Sheet
Price: $6.29 -1.87%

Rating Summary:
    3 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 14 | Down: 11 | New: 8
Trade KDMN Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

H.C. Wainwright initiated coverage on Kadmon Holdings (NYSE: KDMN) with a Buy rating and a price target of $25. Analyst Andrew Fein noted its diverse pipeline.

"In our view, there are three kinds of biotech companies: (a) the first kind offers hard-to-value early-stage science under a strong team with a proven track record (usually a Boston spin-out favorite template); (b) the second kind offers a near-clinical or clinical agent/class with a novel MoA, typically as a high-risk and high-reward program; and (c) the third kind offers an agent/class with a de-risked and established MoA, and typically the price to pay for such “old reliable” science is the pressure of competition. In our view, Kadmon combines the best features of those three categories in one company," said the analyst.

For an analyst ratings summary and ratings history on Kadmon Holdings click here. For more ratings news on Kadmon Holdings click here.

Shares of Kadmon Holdings closed at $9.97 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View, New Coverage

Related Entities

H.C. Wainwright

Add Your Comment